Suppr超能文献

用于药物递送和组织工程应用的模块化、生物相容性硫醇化明胶微粒平台的开发。

Development of a modular, biocompatible thiolated gelatin microparticle platform for drug delivery and tissue engineering applications.

作者信息

Pearce Hannah A, Kim Yu Seon, Watson Emma, Bahrami Kiana, Smoak Mollie M, Jiang Emily Y, Elder Michael, Shannon Tate, Mikos Antonios G

机构信息

Department of Bioengineering, Rice University, 6500 Main Street, Houston, TX 77030, USA.

出版信息

Regen Biomater. 2021 Feb 28;8(3):rbab012. doi: 10.1093/rb/rbab012. eCollection 2021 Jun.

Abstract

The field of biomaterials has advanced significantly in the past decade. With the growing need for high-throughput manufacturing and screening, the need for modular materials that enable streamlined fabrication and analysis of tissue engineering and drug delivery schema has emerged. Microparticles are a powerful platform that have demonstrated promise in enabling these technologies without the need to modify a bulk scaffold. This building block paradigm of using microparticles within larger scaffolds to control cell ratios, growth factors and drug release holds promise. Gelatin microparticles (GMPs) are a well-established platform for cell, drug and growth factor delivery. One of the challenges in using GMPs though is the limited ability to modify the gelatin post-fabrication. In the present work, we hypothesized that by thiolating gelatin before microparticle formation, a versatile platform would be created that preserves the cytocompatibility of gelatin, while enabling post-fabrication modification. The thiols were not found to significantly impact the physicochemical properties of the microparticles. Moreover, the thiolated GMPs were demonstrated to be a biocompatible and robust platform for mesenchymal stem cell attachment. Additionally, the thiolated particles were able to be covalently modified with a maleimide-bearing fluorescent dye and a peptide, demonstrating their promise as a modular platform for tissue engineering and drug delivery applications.

摘要

在过去十年中,生物材料领域取得了显著进展。随着对高通量制造和筛选的需求不断增加,对能够简化组织工程和药物递送方案制造与分析的模块化材料的需求应运而生。微粒是一个强大的平台,已证明有望实现这些技术,而无需对整体支架进行改性。这种在较大支架内使用微粒来控制细胞比例、生长因子和药物释放的构建模块范式具有前景。明胶微粒(GMPs)是用于细胞、药物和生长因子递送的成熟平台。然而,使用GMPs的挑战之一是微粒制备后对明胶进行改性的能力有限。在本研究中,我们假设在微粒形成前对明胶进行硫醇化处理,将创建一个通用平台,既能保留明胶的细胞相容性,又能实现制备后改性。结果发现硫醇对微粒的物理化学性质没有显著影响。此外,硫醇化的GMPs被证明是间充质干细胞附着的生物相容性和稳健平台。此外,硫醇化微粒能够与带有马来酰亚胺的荧光染料和肽进行共价修饰,证明了它们作为组织工程和药物递送应用模块化平台的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db67/8240604/411e8f8578ed/rbab012f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验